Michael Gelband’s Janux Therapeutics JANX Stock Holding History

Michael Gelband’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155K	Sell	10,079 -104,493	-91%	-$1.51M	﹤0.01%	1439
2026 Q1	$1.59M	Sell	114,572 -46,976	-29%	-$644K	0.01%	858
2025 Q4	$2.23M	Buy	+161,548	New	+$3.8M	0.02%	732
2025 Q3	–	Sell	-74,715	Closed	-$1.73M	–	1772
2025 Q2	$1.73M	Buy	74,715 +46,751	+167%	+$1.23M	0.02%	796
2025 Q1	$755K	Buy	+27,964	New	+$1.05M	0.01%	995
2024 Q4	–	Sell	-6,413	Closed	-$291K	–	1768
2024 Q3	$291K	Buy	+6,413	New	+$279K	﹤0.01%	1369
2021 Q3	–	Sell	-24,567	Closed	-$613K	–	2382
2021 Q2	$613K	Buy	+24,567	New	+$547K	0.01%	1255

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Michael Gelband's JANX Position: Q2 2026 in Review

Michael Gelband reduced its Janux Therapeutics (JANX) stake by 91% in Q2 2026, selling an estimated $1.51M and leaving 10,079 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

Michael Gelband first reported a position in JANX in Q2 2021 and has held it in 7 quarters since. The position peaked at $2.23M in Q4 2025. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Michael Gelband held 10,079 shares of Janux Therapeutics worth $155K as of Q2 2026.
Michael Gelband sold 104,493 Janux Therapeutics shares in Q2 2026, an estimated $1.51M.
Janux Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1439 holding.
Michael Gelband first reported a position in Janux Therapeutics in Q2 2021 and has held it in 7 quarters since.
Michael Gelband's Janux Therapeutics position peaked at $2.23M in Q4 2025.
196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.